Core Insights - TGS has secured a 4D streamer acquisition contract in the North Sea, offshore Norway, with a survey scheduled to begin in Q2 2026 and expected to last approximately 65 days [1] Company Overview - TGS is a leading provider of energy data and intelligence, offering advanced data and technology solutions across the entire energy value chain [3] - The company utilizes proprietary GeoStreamer technology and Ramform-designed vessels to deliver high-quality data for optimizing oil and gas production [2] Contract Details - The contract is awarded to TGS by a repeat customer, indicating a strong relationship and trust in TGS's capabilities [2] - The survey will be conducted using a Ramform vessel, showcasing TGS's advanced technological capabilities in the energy sector [1][2]

Core Insights - Addex Therapeutics announced the publication of data in *Molecular Psychiatry* indicating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators (NAM) could significantly improve treatment for anxiety and fear-related disorders, including PTSD [2][3] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [9] - The company's lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury [9] - Addex has a 20% equity interest in Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including mGlu7 NAM for mood disorders [9] Research Findings - The study conducted by scientists from the Center for Psychiatric Neurosciences demonstrated that ADX71743, a selective mGlu7 NAM, can disrupt the reconsolidation of fear memories, which is a critical process in the treatment of anxiety and trauma-related conditions [3][4] - Administration of ADX71743 in rat models showed a significant decrease in the reinstatement of fear, indicating its potential as a therapeutic intervention [4][5] - Electrophysiological analyses revealed that ADX71743 modulated glutamatergic transmission at thalamus-to-amygdala synapses, which are essential for fear learning, providing mechanistic support for its effects [5][6] Market Context - Anxiety and stress-related disorders are among the most prevalent neuropsychiatric conditions globally, with many patients experiencing inadequate responses to existing therapies [4] - Current treatments often target symptoms and require continuous use, leading to risks of tolerance and dependence, highlighting the need for innovative therapeutic approaches [4][6] Future Implications - The research suggests that targeting memory reconsolidation with mGlu7 NAMs could offer a time-limited pharmacological intervention, potentially providing a more durable solution for pathological fear compared to continuous symptom-suppressing medications [6] - The findings support the long-term belief of Addex in the differentiated mechanism of targeting mGlu7 for treating anxiety and fear-related disorders [4][6]

Core Insights - Pharming Group N.V. has announced its financial guidance for 2026, projecting total revenues between US$405 million and US$425 million, representing an 8% to 13% growth [3][7][8] - The company will highlight its advancing clinical-stage pipeline, focusing on two major programs targeting primary immunodeficiencies and mitochondrial diseases during its Investor Day [2][4][6] Financial Guidance - Total revenue guidance for 2026 is set between US$405 million and US$425 million, driven by growth in its commercial products [3][8] - Total operating expenses are expected to be between US$330 million and US$335 million, primarily due to increased R&D expenses related to ongoing clinical trials [7][8] Pipeline Overview - Leniolisib is being developed for primary immunodeficiencies with immune dysregulation, with ongoing Phase II trials expected to yield top-line data in the second half of 2026 [4][5] - Napazimone (KL1333) is being developed for mtDNA-driven mitochondrial disease, with a pivotal clinical trial ongoing and results anticipated in 2027 [6][9] Clinical Programs - Leniolisib is currently approved as Joenja in the U.S. and is the first targeted treatment for activated PI3Kδ syndrome, with potential applicability across broader patient populations [5][6] - Napazimone (KL1333) aims to become the first standard of care for mtDNA-driven mitochondrial disease, addressing significant unmet medical needs [6][9] Investor Day Details - The Investor Day will feature presentations from clinical experts discussing disease biology and the potential impact of Pharming's programs [10][16] - The event is scheduled for February 3, 2026, from 10:00 a.m. to 12:00 p.m. EST, and will be available via webcast [11]

Core Insights - Sika has expanded its global manufacturing footprint by opening five new plants in the United States, Argentina, Colombia, Bangladesh, and Tanzania, enhancing production capacity and supply chain flexibility in key growth markets [1] Group 1: United States - A new concrete admixture facility has been opened in Haines City, Florida, utilizing the highest level of automation among Sika's admixture sites in the country, aimed at improving concrete performance and sustainability [2] - The facility is expected to reduce carbon emissions by approximately 8,000 tons by 2032 due to its water- and waste-reduction systems [2] Group 2: Argentina - A new manufacturing facility in Puerto Tirol, Chaco, will produce dry mortar products for the Northeast region, marking Sika's eighth production site in Argentina [3] - The Argentinian construction market is recovering, providing opportunities for Sika to enhance market penetration and customer engagement [3] Group 3: Colombia - A modern manufacturing site has been established in Cali, Colombia, which produces various construction materials to meet the growing demands of the region [4] - The Cali facility will improve Sika's efficiency in serving both domestic and export markets [4] Group 4: Bangladesh - The new site in Narayanganj manufactures concrete admixtures and mortars, supporting the fast-growing construction market in Bangladesh [5] - The facility will also cater to the demand for Sika's high-performance tile adhesive recently launched in the region [5] - The Bangladeshi construction market is projected to grow at a CAGR of over 7% from 2026 to 2029, driven by investments in infrastructure and housing [6] Group 5: Tanzania - A new production site has been established in Mwanza, Tanzania, focusing on mortars, admixtures, and specialized grouts for mining and construction [7] - The facility serves local demand and exports to neighboring countries, enhancing Sika's presence in East Africa amid strong industrial growth [7] - Tanzania's construction market is expected to continue expanding at a mid-high single-digit rate in the coming years [7] Group 6: Corporate Profile - Sika is a leading specialty chemicals company with a global presence, operating in 102 countries and producing in over 400 factories [8] - The company generated CHF 11.20 billion in sales in 2025, employing approximately 33,000 individuals [8]

Core Viewpoint - Sanofi has announced a share buyback program of up to €1 billion, set to take place between February 3, 2026, and December 31, 2026 [1] Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare and societal challenges [2] Share Buyback Program Details - The share buyback program is authorized for a total consideration of up to €1 billion, with a mandate signed with an investment service provider on February 2, 2026 [1][6]

WISeKey to ConnectWISeRobot.CH to the WISeSat.Space Constellation protected by SEALSQ Post-Quantum Cryptography; The Robot PoC will be showcased at WISeKEY’s CEO Carlos Moreira’s next public appearance in France at Tech & Fest Video link is available at https://youtube.com/shorts/XsVQlcDtfTQ Geneva, Switzerland — February 3, 2026 –WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that during the next WISeSat ...

Update on Recent Incidents at Palito Complex and Coringa Mine Serabi Gold plc (“Serabi” or the “Company”) (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, provided the following update regarding last week’s incidents at Palito Complex and Coringa mine. The Company confirms that mining and milling operations were at no point interrupted and continue to progress according to budget. The Company has complied with protocols of all relevant agencies and authorities rega ...

eQ Plc Stock Exchange Release 3 February 2026 at 8:00 AM eQ is renewing the composition of its Management Team to support the implementation of the strategy and the management of the Group. eQ's Board of Directors has appointed the Group’s Management Team and the new Management Team will start its work on 3 February 2026 under the leadership of CEO Jouko Pölönen. Composition of the Management Team from 3 February 2026: Jouko Pölönen, CEO of eQ Plc, M.Sc. (Econ.), EMBA (born 1970)Tero Estovirta, CEO of eQ As ...

eQ Plc financial statements release3 February 2026 at 8:00 a.m. January to December 2025 in brief The Group's net revenue for the reporting period was EUR 58.2 million (EUR 65.6 million 1 January - 31 December 2024). The Group’s net fee and commission income was EUR 58.5 million (EUR 63.8 million). The Group’s operating profit fell by 21% to EUR 27.4 million (EUR 34.5 million).Earnings per share were EUR 0.52 (EUR 0.66).Net revenue in the Asset Management segment decreased by 3 per cent to 56.9 million eur ...

Amundi: Fourth quarter & Full-year 2025 results Successful launch of the new strategic plan: Record annual net inflows +€88bn & pre-tax income1 up +6%2 vs. 2024 Very dynamic activity Record assets under management3, at €2,380bn at end-December, +6% year-on-yearRecord net inflows of +€88bn in 2025, of which +€21bn in Q4 Positive inflows in both passive management (+€76bn) and active management (+€13bn) thanks to fixed income and multi-asset strategies Positive inflows from Retail, Institutional and joint ven ...